Skip to main content

Table 2 Designated and estimated prevalence of two vaccine-associated high-risk types by Linear Array (LA)-only and sequential testing strategies in the United States and Latin America

From: Comparison of DNA testing strategies in monitoring human papillomavirus infection prevalence through simulation

Genotyping assay performance Time Designated composite prevalence (SD) LA only Sequential testing
Composite prevalence estimate (SD) Estimate-to-true ratio Composite prevalence estimate (SD) Estimate-to-true ratio
United States
Sen = 1.00
Spe = 1.00
Baseline 0.064 (0.004) 0.064 (0.004) 1.000 0.029 (0.003) 0.453
Reduced 0.032 (0.003) 0.032 (0.003) 1.000 0.015 (0.002) 0.469
% reduction 50 50   48  
Sen = 0.95
Spe = 0.95
Baseline 0.064 (0.004) 0.151 (0.006) 2.359 0.068 (0.004) 1.063
Reduced 0.032 (0.003) 0.124 (0.005) 3.875 0.056 (0.004) 1.750
% Reduction 50 17.9   17.6  
Sen = 0.95
Spe = 0.90
Baseline 0.064 (0.004) 0.287 (0.007) 4.484 0.107 (0.005) 1.672
Reduced 0.032 (0.003) 0.213 (0.006) 6.656 0.096 (0.004) 3.000
% Reduction 50 25.8   10.3  
Sen = 0.90
Spe = 0.90
Baseline 0.064 (0.004) 0.234 (0.007) 3.656 0.105 (0.005) 1.641
Reduced 0.032 (0.003) 0.211 (0.006) 6.594 0.095 (0.005) 2.969
% Reduction 0.50 9.8   9.5  
Sen = 0.90
Spe = 0.85
Baseline 0.064 (0.004) 0.314 (0.008) 4.906 0.142 (0.006) 2.219
Reduced 0.032 (0.003) 0.294 (0.007) 9.188 0.132 (0.006) 4.125
% Reduction 50 6.4   7.0  
Sen = 0.85
Spe = 0.85
Baseline 0.064 (0.004) 0.312 (0.007) 4.875 0.141 (0.005) 2.219
Reduced 0.032 (0.003) 0.293 (0.008) 9.156 0.132 (0.005) 4.125
% Reduction 50 42   7.0  
Sen = 0.80
Spe = 0.80
Baseline 0.064 (0.004) 0.385 (0.008) 6.016 0.173 (0.006) 2.703
Reduced 0.032 (0.003) 0.371 (0.007) 11.594 0.167 (0.005) 5.219
% Reduction 50 4.2   3.5  
Latin America
Sen = 1.00
Spe = 1.00
Baseline 0.045 (0.003) 0.045 (0.003) 1.000 0.020 (0.002) 0.444
Reduced 0.022 (0.002) 0.022 (0.002) 1.000 0.010 (0.002) 0.455
% Reduction 51 5.1   5.0  
Sen = 0.95
Spe = 0.95
Baseline 0.045 (0.003) 0.135 (0.005) 3.000 0.060 (0.004) 1.333
Reduced 0.022 (0.002) 0.116 (0.005) 5.273 0.052 (0.003) 2.364
% Reduction 51 14.1   13.3  
Sen = 0.95
Spe = 0.90
Baseline 0.045 (0.003) 0.222 (0.007) 4.933 0.099 (0.005) 2.200
Reduced 0.022 (0.002) 0.205 (0.006) 9.318 0.093 (0.005) 4.227
% Reduction 51 7.6   6.1  
Sen = 0.90
Spe = 0.90
Baseline 0.045 (0.003) 0.219 (0.006) 4.867 0.099 (0.005) 2.200
Reduced 0.022 (0.002) 0.204 (0.006) 8.870 0.092 (0.005) 4.000
% Reduction 51 6.8   7.1  
Sen = 0.90
Spe = 0.85
Baseline 0.045 (0.003) 0.302 (0.007) 6.711 0.136 (0.005) 3.022
Reduced 0.022 (0.002) 0.288 (0.007) 13.091 0.130 (0.005) 5.909
% Reduction 51 4.6   4.4  
Sen = 0.85
Spe = 0.85
Baseline 0.045 (0.003) 0.300 (0.007) 6.667 0.135 (0.005) 3.000
Reduced 0.022 (0.002) 0.288 (0.007) 13.091 0.129 (0.005) 5.864
% Reduction 51 4.6   4.4  
Sen = 0.80
Spe = 0.80
Baseline 0.044 (0.003) 0.376 (0.007) 8.545 0.169 (0.006) 3.841
Reduced 0.022 (0.002) 0.366 (0.007) 16.63 0.165 (0.006) 7.500
% Reduction 50 2.7   2.4  
  1. Type-specific prevalence at baseline, in the United States: HPV16 = 0.047 and HPV18 = 0.019; in Latin America: HPV16 = 0.033 and HPV18 = 0.012
  2. Reduced: HPV16 and HPV18 are reduced by 50 %
  3. Abbreviations: SD standard deviation, Sen, sensitivity, Spe, specificity